KBKathleen S. Bingham

Kathleen S. Bingham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen S. Bingham has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Alastair J. Flint

    Department of Psychiatry, University of Toronto, Toronto, Canada

    8 shared publications
  • Alastair J. Flint

    Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Centre for Mental Health, University Health Network, Toronto, Ontario, Canada

    6 shared publications
  • Benoit H. Mulsant

    Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Canada

    6 shared publications
  • Zahi Touma

    University of Toronto Toronto Ontario Canada

    6 shared publications
  • Barnett S. Meyers

    Department of Psychiatry, Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, New York, USA

    5 shared publications
  • Dennisse Bonilla

    Schroeder Arthritis Institute and Krembil Research Institute, University Health Network and University of Toronto Lupus Clinic, Toronto Western Hospital Toronto Ontario Canada

    4 shared publications

Latest Publications

  • Open Access

    Evidence for models of integrated dementia care: a scoping review protocol

    by Kathleen S. Bingham, Y. Isabella Lim, Jasleen Jagayat, Margot Sigel, Junqiang Zhao, Jolene Wintermute, Alastair J. Flint, Sandra Easson-Bruno, Salinda Horgan

  • Open Access

    Association of Elevated Serum S100A8 / A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus

    by Carolina Muñoz‐Grajales, Michelle L. Barraclough, Juan P. Diaz‐Martinez, Jiandong Su, Kathleen Bingham, Mahta Kakvan, Roberta Pozzi Kretzmann, Maria Carmela Tartaglia, Lesley Ruttan, May Y. Choi, et al.

    Objective: Cognitive impairment (CI) is common in patients with systemic lupus erythematosus (SLE). Despite its prevalence, the immune mechanisms are not well understood. We previously reported elevated serum levels of S100A8/A9 and matrix metalloproteinase 9 (MMP‐9) in patients with SLE and CI. This study aims to validate those findings by examining the relationship between serum levels and CI in patients with SLE at baseline and after one year. Methods: We assessed cognitive function in 112 patients with SLE using the adapted American College of Rheumatology–Neuropsychological Battery, defining CI as impairment in two or more domains. Serum S100A8/A9 and MMP‐9 levels were measured by enzyme‐linked immunosorbent assay. We compared serum levels between CI and non‐CI groups, evaluated cognitive domain performance at baseline and one year, and explored associations between serum changes and cognitive status changes. Results: At baseline, 48 patients (42.8%) had CI. After one year, the cognitive funtion remained stable in 55%, improved in 31.2%, and worsened in 13% of patients. Serum S100A8/A9 levels were significantly higher in CI patients at baseline ( P = 0.0007, r = 0.413) and one year ( P = 0.0045, r = 0.359), correlating inversely with multiple CI domains. The worsened group showed a significant increase in S100A8/A9 levels, whereas the improved group exhibited a reduction. Conclusion: In this large cohort of patients with well‐characterized SLE, serum S100A8/A9 levels were elevated in those with CI and showed an inverse relationship with cognitive performance across multiple domains. Changes in S100A8/A9 levels corresponded with changes in cognitive status over one year. These findings warrant further investigation into the role of S100A8/A9 in CI within the context of SLE.


  • Predicting anxiety and depression in systemic lupus erythematosus: the role of inflammation, sociodemographic variables and clinical factors

    by Margot Sigel, Carolina Muñoz-Grajales, Michelle L. Barraclough, Juan P Diaz-Martinez, Mahta Kakvan, Roberta Pozzi Kretzmann, M Carmela Tartaglia, Lesley Ruttan, May Y Choi, Simone Appenzeller, et al.


  • Open Access

    Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial

    by Ryma A. Ihaddadene, George S. Alexopoulos, Patricia Marino, Barnett S. Meyers, Benoit H. Mulsant, Nicholas H. Neufeld, Anthony J. Rothschild, Aristotle N. Voineskos, Ellen M. Whyte, Alastair J. Flint, et al.


  • Open Access

    Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life

    by Ambika Gupta, Sindhu Johnson, Michelle Barraclough, Jiandong Su, Kathleen Bingham, Andrea M Knight, Juan Pablo Diaz Martinez, Mahta Kakvan, Maria Carmela Tartaglia, Lesley Ruttan, et al.

    Objective: To determine if self-reported fatigue, anxiety, depression, cognitive difficulties, health-related quality of life, disease activity scores and neuropsychological battery (NB) cluster into distinct groups in patients with SLE based on symptom intensity and if they change at 1-year follow-up.Methods: This is a retrospective analysis of consecutive consenting patients, followed at a single centre. Patients completed a comprehensive NB, the Beck Anxiety Inventory, Beck Depression Inventory, Fatigue Severity Scale, Short-Form Health Survey Physical Component Summary and Mental Component Summary scores and the Perceived Deficits Questionnaire. Disease activity was assessed by Systemic Lupus Erythematosus Disease Activity Index 2000. Ward’s method was used for clustering and principal component analysis was used to visualise the number of clusters. Stability at 1 year was assessed with kappa statistic.Results: Among 142 patients, three clusters were found:cluster 1had mild symptom intensity,cluster 2had moderate symptom intensity andcluster 3had severe symptom intensity. At 1-year follow-up, 49% of patients remained in their baseline cluster. The mild cluster had the highest stability (77% of patients stayed in the same cluster), followed by the severe cluster (51%), and moderate cluster had the lowest stability (3%). A minority of patients from mild cluster moved to severe cluster (19%). In severe cluster, a larger number moved to moderate cluster (40%) and fewer to mild cluster (9%).Conclusion: Three distinct clusters of symptom intensity were documented in patients with SLE in association with cognitive function. There was a lower tendency for patients in the mild and severe clusters to move but not moderate cluster over the course of a year. This may demonstrate an opportunity for intervention to have moderate cluster patients move to mild cluster instead of moving to severe cluster. Further studies are necessary to assess factors that affect movement into moderate cluster.


  • Open Access

    Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis

    by Fernanda Onofrio, Katina Zheng, Cherry Xu, Shiyi Chen, Wei Xu, Mary Vyas, Katie Bingham, Keyur Patel, Leslie Lilly, Mark Cattral, et al.

    Background: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with PSC. We sought to describe and analyze the clinical trajectory for patients with PSC referred for LT, in a mixed deceased donor/living donor transplant program. Methods: This was a retrospective cohort study from November 2012 to December 2019, including all patients with PSC referred for assessment at the University Health Network Liver Transplant Clinic. Patients who required multiorgan transplant or retransplantation were excluded. Liver symptoms, hepatobiliary malignancy, MELD-Na progression, and death were abstracted from chart review. Competing risk analysis was used for timing of LT, transplant type, and death. Results: Of 172 PSC patients assessed, 84% (n = 144) were listed of whom 74% were transplanted. Mean age was 47.6 years, and 66% were male. Overall mortality was 18.2% at 2 years. During the follow-up, 16% (n = 23) were removed from the waitlist for infection, clinical deterioration, liver-related mortality or new cancer; 3 had clinical improvement. At listing, 82% (n = 118) had a potential living donor (pLD). Patients with pLD had significantly lower waitlist and liver-related waitlist mortality (HR 0.20, ppp = 0.05). Exception points were granted to 13/172 (7.5%) patients. Conclusions: In a high-volume North American LT center, most patients with PSC assessed for transplant were listed and subsequently transplanted. However, this was a consequence of patients engaging in living donor transplantation. Our findings support the concern from patients with PSC that MELD-Na allocation does not adequately address their needs.


  • The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression

    by Kathleen S. Bingham, Navona Calarco, Erin W. Dickie, George S. Alexopoulos, Meryl A. Butters, Barnett S. Meyers, Patricia Marino, Nicholas H. Neufeld, Anthony J. Rothschild, Ellen M. Whyte, et al.


  • Assessing the Utility of the Montreal Cognitive Assessment in Screening for Cognitive Impairment in Patients With Systemic Lupus Erythematosus

    by Oshrat E. Tayer‐Shifman, Kimberley Yuen, Robin Green, Mahta Kakvan, Patricia Katz, Kathleen S. Bingham, Juan Pablo Diaz‐Martinez, Lesley Ruttan, Joan E. Wither, Maria Carmela Tartaglia, et al.

    Objective: Screening for cognitive impairment (CI) in systemic lupus erythematosus (SLE) relies on the American College of Rheumatology (ACR) neuropsychological battery (NB). By studying the concurrent criterion validity, our goal was to assess the Montreal Cognitive Assessment (MoCA) as a screening tool for CI compared to the ACR‐NB and to evaluate the added value of the MoCA to the Automated Neuropsychological Assessment Metrics (ANAM).Methods: A total of 285 adult SLE patients were administered the ACR‐NB, MoCA, and ANAM. For the ACR‐NB, patients were classified as having CI if there was a Z score of ≤–1.5 in ≥2 domains. The area under the curve (AUC) and sensitivities/specificities were determined. A discriminant function analysis was applied to assess the ability of the MoCA to differentiate between CI, undetermined CI, and non‐CI patients.Results: CI was not accurately identified by the MoCA compared to the ACR‐NB (AUC of 0.66). Sensitivity and specificity were poor at 50% and 69%, respectively, for the cutoff of 26, and 80% and 45%, respectively, for the cutoff of 28. The MoCA had a low ability to identify CI status. The addition of the MoCA to the ANAM led to improvement on the AUC by only 2.5%.Conclusion: The MoCA does not have adequate concurrent criterion validity to accurately identify CI in patients with SLE. The low specificity of the MoCA may lead to overdiagnosis and concern among patients. Adding the MoCA to the ANAM does not substantially improve the accuracy of the ANAM. These results do not support using the MoCA as a screening tool for CI in patients with SLE.


  • Open Access

    Prevalence, causes, and consequences of moral distress in healthcare providers caring for people living with dementia in long-term care during a pandemic

    by Lynn Haslam-Larmer, Alisa Grigorovich, Hannah Quirt, Katia Engel, Steven Stewart, Kevin Rodrigues, Pia Kontos, Arlene Astell, Josephine McMurray, AnneMarie Levy, et al.

    Healthcare providers caring for people living with dementia may experience moral distress when faced with ethically challenging situations, such as the inability to provide care that is consistent with their values. The COVID-19 pandemic produced conditions in long-term care homes (hereafter referred to as ‘care homes’) that could potentially contribute to moral distress. We conducted an online survey to examine changes in moral distress during the pandemic, its contributing factors and correlates, and its impact on the well-being of care home staff. Survey participants (n = 227) working in care homes across Ontario, Canada were recruited through provincial care home organizations. Using a Bayesian approach, we examined the association between moral distress and staff demographics and roles, and characteristics of the long-term care home. We performed a qualitative analysis of the survey’s free-text responses. More than 80% of care home healthcare providers working with people with dementia reported an increase in moral distress since the start of the pandemic. There was no difference in the severity of distress by age, sex, role, or years of experience. The most common factors associated with moral distress were lack of activities and family visits, insufficient staffing and high turnover, and having to follow policies and procedures that were perceived to harm residents with dementia. At least two-thirds of respondents reported feelings of physical exhaustion, sadness/anxiety, frustration, powerlessness, and guilt due to the moral distress experienced during the pandemic. Respondents working in not-for-profit or municipal homes reported less sadness/anxiety and feelings of not wanting to go to work than those in for-profit homes. Front-line staff were more likely to report not wanting to work than those in management or administrative positions. Overall, we found that increases in moral distress during the pandemic negatively affected the well-being of healthcare providers in care homes, with preliminary evidence suggesting that individual and systemic factors may intensify the negative effect.


  • Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study

    by Kathleen S. Bingham, Nicholas H. Neufeld, George S. Alexopoulos, Patricia Marino, Benoit H. Mulsant, Anthony J. Rothschild, Aristotle N. Voineskos, Ellen M. Whyte, Barnett S. Meyers, Alastair J. Flint